Older adults generally need far less THC than younger users, and most clinical protocols start at very low amounts, often around 1 to 2.5 mg per dose. The reason is straightforward: aging changes how the body absorbs, distributes, and clears THC, which means the same dose that produces a mild effect in a 30-year-old can hit much harder in a 75-year-old. Most geriatric cannabis research emphasizes CBD-dominant or balanced THC-to-CBD products rather than high-THC formulations, and the guiding principle across the board is “start low, go slow.”
Why the Same Dose Hits Harder After 65
THC dissolves readily into fat tissue, and as people age, their body composition shifts toward a higher proportion of fat relative to lean muscle. That matters because THC essentially gets absorbed into fat stores and released slowly over time, prolonging its effects. Older adults also have reduced blood flow through the liver and changes in how liver enzymes break down THC and its active byproduct, 11-hydroxy-THC. The net result is that THC lingers longer in an older person’s body and produces a more sustained exposure than it would in someone younger.
1PubMed Central. Cannabinoid neuropharmacology across the lifespan: how aging recalibrates risk and benefitThis extended exposure is not just academic. It translates directly into stronger psychoactive effects, more pronounced sedation, and a longer recovery window after each dose. For someone on multiple medications already affecting alertness or blood pressure, that prolonged THC activity compounds the risks in ways that a younger, healthier person would not experience. It also means that dose adjustments in older adults should happen more slowly, with longer intervals between increases, because the full effect of a given dose may not be apparent for several days.
What “Low Dose” Actually Looks Like in Practice
There is no single universally agreed-upon starting dose for older adults, but the clinical studies that exist cluster around similar numbers. In a randomized trial of THC for dementia-related behavioral symptoms, researchers used 1.5 mg of oral THC given three times daily, totaling 4.5 mg per day. That dose was well tolerated, with no significant difference in adverse events between the THC group and the placebo group, though it also did not outperform placebo for the symptoms being studied.
2PubMed Central. Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trialA separate trial looking at appetite stimulation in older patients with poor appetite used a higher dose of about 8 mg of THC (combined with roughly 7.5 mg of CBD) given as two doses on the same day. That regimen was generally tolerated but did not improve caloric intake compared to placebo.
3PubMed. The appetite stimulating effect and safety of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in older patients with poor appetite: A triple-blinded, randomized, placebo-controlled, cross-over trialThese numbers give you a rough range. Most clinicians working with older adults recommend starting at 1 to 2.5 mg of THC per dose and increasing by small increments, sometimes no more than 1 mg at a time, over periods of a week or more. The goal is to find the lowest effective dose rather than to escalate quickly. In a large observational study of patients with a mean age of about 81, this cautious approach kept roughly six in ten patients on cannabis at the six-month mark, with the majority reporting at least some improvement in their overall condition.
4PubMed Central. Medical Cannabis for Older Patients-Treatment Protocol and Initial ResultsWhy CBD-Dominant Products Come Up So Often
When doctors authorize cannabis for older adults, they overwhelmingly lean toward products that are either CBD-dominant or have a balanced ratio of CBD to THC. In one Canadian cohort study of older patients, CBD-dominant products were authorized most frequently, accounting for more than half of all authorizations, while balanced CBD-to-THC products made up about two in five. THC-dominant products were authorized for fewer than one in twenty patients.
5PubMed Central. Medical cannabis authorization patterns, safety, and associated effects in older adultsThe rationale is that CBD can temper some of THC’s less desirable effects, particularly anxiety, confusion, and excessive sedation. For older adults who are more vulnerable to those side effects, pairing THC with CBD acts as a partial buffer. A balanced or CBD-dominant product lets patients get some of the therapeutic benefits attributed to THC, such as pain relief and sleep improvement, while reducing the risk of the cognitive fog or disorientation that pure THC can cause. This does not mean THC-dominant products are never appropriate for older adults, but the evidence and clinical practice both favor starting with formulations where THC is not the sole or primary cannabinoid.
Side Effects That Matter Most in Older Adults
The side effect profile of THC in older adults tracks with what you would expect from prolonged, amplified exposure: dizziness, excessive sleepiness, and fatigue top the list. In the large observational study of patients averaging 81 years old, about a third of patients on cannabis reported some adverse event, with dizziness affecting roughly one in eight and sleepiness or fatigue affecting a similar proportion.
6PubMed Central. Medical Cannabis for Older Patients-Treatment Protocol and Initial ResultsA broader review of cannabinoid use in older adults found that sedation and lethargy were the most commonly reported adverse effects across studies, with modest reductions in cognitive performance appearing more often at higher doses and with heavier lifetime use.
7PubMed Central. A Systematic Review of the Neurocognitive Effects of Cannabis Use in Older AdultsThese effects might sound manageable in isolation, but for an 80-year-old with balance issues, dizziness is not a minor inconvenience. It can be the difference between a safe evening and a broken hip. That connection between side effects and real-world consequences is what makes dose selection in this population genuinely high-stakes rather than a matter of personal comfort.
Falls, Balance, and Why Dizziness Is Not Just Annoying
Falls are a leading cause of serious injury and loss of independence in older adults, and THC introduces several mechanisms that can tip the scales. Research comparing older cannabis users to non-users found higher fall risk, worse single-leg balance, and slower walking speed in the cannabis group.
8PubMed Central. Increased Likelihood of Falling in Older Cannabis Users vs. Non-UsersA controlled crossover trial in community-dwelling dementia patients (average age 77) specifically tested whether low-dose THC, 1.5 mg twice daily, affected balance and walking. THC significantly increased body sway when patients stood with their eyes closed and altered their walking pattern, increasing stride length and trunk sway. However, no falls actually occurred during the study, and the researchers described the adverse event profile of 3 mg per day as benign regarding mobility in this population.
9PubMed. Effects of tetrahydrocannabinol on balance and gait in patients with dementia: A randomised controlled crossover trialThere is also a cardiovascular angle to the fall risk. THC can cause orthostatic hypotension, the sudden drop in blood pressure that happens when you stand up from sitting or lying down. In older adults, that blood pressure drop can cause lightheadedness or even fainting, and combined with THC’s effects on balance, the risk of falling and sustaining injury increases.
10Canadian Journal of Cardiology. Managing Cannabis Use in Patients With Cardiovascular DiseaseThe practical takeaway is that timing matters as much as dose. Taking THC before bed rather than before an activity that involves standing and moving can reduce fall risk substantially. Patients who do take THC during the day should be cautious about standing up quickly and should be aware of the effects on their balance, especially in poorly lit rooms or on uneven surfaces.
Drug Interactions and the Polypharmacy Problem
The average older adult takes multiple prescription medications, and THC does not exist in a pharmacological vacuum. Both THC and CBD interact with a family of liver enzymes that metabolize a wide range of common drugs. THC inhibits several of these enzymes, including ones responsible for breaking down blood thinners, heart medications, central nervous system drugs, certain pain medications, and gastrointestinal drugs. CBD has an even broader inhibitory profile across these same enzyme pathways.
11Medical Cannabis and Cannabinoids Journal. A Review of Drug-Drug Interactions involving Medical Cannabis in Older AdultsWhen THC or CBD slows down the enzyme that clears another drug from the body, that other drug effectively becomes a higher dose. If you are on a blood thinner and start taking cannabis, the blood thinner may stay active longer and at higher levels than intended, raising the risk of bleeding. The same logic applies to sedatives, antidepressants, and many other medications common in older adults. This is one of the strongest arguments for involving a pharmacist or physician in any decision to add cannabis to an existing medication regimen, even if the THC dose itself seems trivially small.
Can THC Replace Other Medications?
One of the more appealing possibilities is that cannabis might allow older adults to reduce or stop other medications, particularly opioids and benzodiazepines, drugs that carry their own serious risks in the elderly. There is some evidence pointing in this direction. In one Israeli study of older cannabis patients, about 18% stopped using opioid painkillers or reduced their dose after six months of cannabis treatment.
12PubMed. Epidemiological characteristics, safety and efficacy of medical cannabis in the elderlyA more recent retrospective study painted a more nuanced picture. At the population level, overall medication burden stayed stable: patients were on a median of five other medications both at baseline and at their last follow-up visit. But when researchers looked at individual patients, they found 23 specific medication reduction events spread across 11 patients, with benzodiazepines being the most commonly reduced or discontinued drug. In all of those cases, the reductions happened alongside documented clinical improvement.
13Research Square. Medical cannabis in older adults: real-world evidence from a retrospective observational studyThe honest read of this evidence is that cannabis helps some older adults reduce specific high-risk medications, but it is not a reliable deprescribing tool across the board. The patients who did reduce medications were the ones who clearly improved. For others, cannabis simply became one more medication in the mix without replacing anything.
Specific Conditions Where Older Adults Try THC
Pain is the most common reason older adults turn to cannabis, followed by sleep problems and, less commonly, appetite loss or agitation related to dementia. The evidence for each of these varies considerably.
For chronic pain, observational data is the strongest. The large study of patients in their 80s found that a majority of those who stayed on cannabis reported improvement in their overall condition, and pain was the primary indication for most of them.
14PubMed Central. Medical Cannabis for Older Patients-Treatment Protocol and Initial ResultsFor sleep, older patients using cannabis specifically for sleep disturbance were more likely to use THC-containing products and to use them frequently, with about three-quarters consuming cannabis daily or weekly.
15PubMed Central. Cannabis use for Sleep Disturbance Among Older Patients in a Geriatrics ClinicFor appetite and weight loss, the evidence is weak. A meta-analysis of cannabinoid interventions for cachexia in cancer patients found no significant benefit for appetite based on very low-quality evidence, although some patient-reported observations from non-randomized studies suggested improvements.
16PubMed Central. Cannabinoid interventions for improving cachexia outcomes in cancer: a systematic review and meta-analysisFor dementia-related agitation, the randomized trial using 4.5 mg of THC daily found no significant benefit over placebo at three weeks, though it was well tolerated. The researchers classified this as strong evidence that low-dose THC does not meaningfully reduce behavioral symptoms in dementia, at least at that dose and timeframe.
17PubMed Central. Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trialHow to Take It and Why the Route Matters
Older adults generally do better with oral or sublingual products rather than inhaled cannabis, for a few reasons. Smoking introduces respiratory irritants that are particularly problematic for people with existing lung conditions, and the rapid onset of inhaled THC makes it harder to control the dose. Edibles and sublingual oils allow for more precise dosing, measured in milligrams rather than puffs, and their slower onset gives both the patient and their caregiver more time to observe the effects before deciding whether to take more.
The tradeoff is that oral THC takes longer to kick in, sometimes 60 to 90 minutes, and its effects last longer. This slower timeline can catch inexperienced users off guard if they take a second dose before the first one has fully taken effect. The first-pass metabolism through the liver also converts more THC to 11-hydroxy-THC, the active metabolite, which is actually more potent than THC itself. For an older adult whose liver is already clearing things slowly, this conversion can amplify the effect beyond what the labeled dose would suggest.
Sublingual administration, where oil is held under the tongue, partially bypasses first-pass liver metabolism and tends to produce effects somewhat faster than swallowed edibles. For older adults who need predictable timing without the respiratory downsides of smoking, sublingual products are often the most practical route.
When Caregivers Are Making the Decisions
A reality that clinical protocols often sidestep is that many older adults who use cannabis are not making the decision independently. For people with dementia or other cognitive impairments, it is frequently a caregiver who decides to try cannabis, obtains it, and administers it. Research looking at cannabis use among people with dementia and their caregivers found that a meaningful number of caregivers were providing cannabis to the person they cared for, typically targeting agitation, sleep disturbances, and other behavioral symptoms.
18PubMed Central. Cannabis Use among Persons with Dementia and Their Caregivers: Lighting up an Emerging Issue for Clinical GerontologistsThis creates a layer of complexity around dosing. A caregiver without clinical guidance may rely on dispensary staff, online forums, or trial and error. The person receiving the cannabis may not be able to communicate whether the dose is too high or describe subtle side effects like dizziness or confusion, symptoms that could easily be attributed to the underlying dementia rather than to the cannabis. If you are a caregiver considering cannabis for someone in your care, working with a physician who can monitor the situation and adjust the dose is genuinely important, not just a pro forma recommendation.
Cardiovascular Risks Worth Knowing About
THC affects the heart and blood vessels in ways that are particularly relevant for older adults. It can raise heart rate acutely and cause orthostatic hypotension, the blood pressure drop on standing that was mentioned earlier in the context of falls. For someone with coronary artery disease, the combination of a faster heart rate and lower blood pressure can worsen blood flow to the heart muscle, potentially aggravating ischemia. The same mechanism can also precipitate stroke in susceptible individuals.
19Canadian Journal of Cardiology. Managing Cannabis Use in Patients With Cardiovascular DiseaseThese risks are dose-dependent, which brings the conversation back to why starting low is not just cautious but specifically protective for the cardiovascular system. They also interact with common medications. An older adult on a beta-blocker or a calcium channel blocker may have an exaggerated blood pressure response to THC because their cardiovascular system is already being modulated pharmacologically. Again, the interplay between THC and existing medications is a recurring theme in geriatric dosing, and it is one of the main reasons that what works for a healthy 40-year-old is not a useful reference point.
What the Research Still Cannot Tell You
The frustrating reality is that most of the evidence for THC dosing in older adults comes from observational studies, small trials, and clinical experience rather than from the kind of large, long-term randomized trials that would give firm answers. The randomized trials that do exist have tested very specific doses for very specific conditions, like the 4.5 mg per day trial for dementia agitation, and their findings do not generalize easily to the many other reasons older adults use cannabis.
There is almost no long-term safety data on daily THC use in people over 75. We do not have reliable data on whether tolerance develops differently in older adults, whether chronic low-dose use affects cognitive decline over years, or how different THC-to-CBD ratios perform head-to-head in this age group. Several research groups have called for randomized controlled trials specifically in older adults, pharmacokinetic studies that account for age-related body changes, and longitudinal safety evaluations. Until those studies are done, dosing guidance for older adults will continue to rely heavily on clinical judgment, cautious titration, and the limited trial data available.